MEI Pharma (NASDAQ:MEIP) Stock Crosses Below 200 Day Moving Average – Should You Sell?

Posted by Simon Gomez on Feb 11th, 2025

MEI Pharma, Inc. (NASDAQ:MEIP – Get Free Report)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.91 and traded as low as $2.67. MEI Pharma shares last traded at $2.77, with a volume of 5,441 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on MEI Pharma in a report on Tuesday. They set a “buy” rating for the company.

Check Out Our Latest Analysis on MEI Pharma

MEI Pharma Stock Performance

The company has a market cap of $18.45 million, a P/E ratio of -0.40 and a beta of 0.79. The stock has a 50-day simple moving average of $2.68 and a 200 day simple moving average of $2.91.

MEI Pharma (NASDAQ:MEIP – Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($1.20) EPS for the quarter. Sell-side analysts anticipate that MEI Pharma, Inc. will post -5.1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On MEI Pharma

An institutional investor recently bought a new position in MEI Pharma stock. World Investment Advisors LLC purchased a new position in MEI Pharma, Inc. (NASDAQ:MEIP – Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $71,000. World Investment Advisors LLC owned approximately 0.38% of MEI Pharma as of its most recent SEC filing. 52.38% of the stock is currently owned by institutional investors and hedge funds.

MEI Pharma Company Profile

(Get Free Report)

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.